#1 HbA1c
Metformin Therapies → HbA1c
Evidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 86
- consistent
Supporting studies: Based on 8 studies
Explore evidenceMedications
Glucose-lowering drugs and other pharmacologic treatments. Use examples: Metformin, insulin analogs, GLP-1 RAs, DPP-4 inhibitors
Last updated: July 15, 2026
Key takeaway
Medications has evidence across 10 diabetes-related outcomes, with strongest support for HbA1c, Body Weight and HbA1c.
Evidence status
Moderate ResearchEvidence Strength: 60/100
Related Evidence Topics
Evidence Intelligence™
Every evidence topic is generated from structured relationships across diabetes research, including topics, interventions, outcomes, and individual studies.
694
Evidence relationships
844
Studies reviewed
33
Outcomes evaluated
Strongest evidence area
HbA1c
Top Interventions
Showing grouped evidence. Expand in Evidence Explorer for detailed intervention-outcome pairs.Open Evidence Explorer
| Rank | Outcome group | EvidenceScore™ | ImpactScore™ | Consistency | Studies | Effectiveness | Action |
|---|---|---|---|---|---|---|---|
| #1 | HbA1c | 88/100Strong | 83/100Positive | 86/100consistent | 8 | moderate_positive | Explore evidence |
| #2 | Body Weight | 87/100Strong | 83/100Positive | 96/100consistent | 26 | moderate_positive | Explore evidence |
| #3 | HbA1c | 87/100Strong | 93/100Very Positive | 93/100consistent | 27 | strong_positive | Explore evidence |
| #4 | Cardiovascular Outcomes | 85/100Strong | 66/100Slightly Positive | 35/100mixed | 12 | weak_positive | Explore evidence |
| #5 | Cardiovascular Outcomes | 84/100Strong | 78/100Positive | 60/100generally_consistent | 5 | moderate_positive | Explore evidence |
| #6 | Insulin Resistance | 83/100Strong | 90/100Very Positive | 100/100consistent | 5 | strong_positive | Explore evidence |
| #7 | CGM Time in Range | 83/100Strong | 75/100Positive | 35/100mixed | 5 | moderate_positive | Explore evidence |
| #8 | Fasting Glucose | 83/100Strong | 69/100Positive | 63/100generally_consistent | 8 | moderate_positive | Explore evidence |
| #9 | HbA1c | 83/100Strong | 87/100Very Positive | 100/100consistent | 7 | strong_positive | Explore evidence |
| #10 | Hypoglycemia | 83/100Strong | 55/100Slightly Positive | 100/100consistent | 12 | weak_positive | Explore evidence |
#2 Body Weight
GLP-1 Receptor Agonists → Body Weight
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 96
- consistent
Supporting studies: Based on 26 studies
Explore evidence#3 HbA1c
GLP-1 Receptor Agonists → HbA1c
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 93
- Very Positive
- ConsistencyScore™
- 93
- consistent
Supporting studies: Based on 27 studies
Explore evidence#4 Cardiovascular Outcomes
GLP-1 Receptor Agonists → Cardiovascular Outcomes
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 66
- Slightly Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 12 studies
Explore evidence#5 Cardiovascular Outcomes
SGLT2 Inhibitors → Cardiovascular Outcomes
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 78
- Positive
- ConsistencyScore™
- 60
- generally_consistent
Supporting studies: Based on 5 studies
Explore evidence#6 Insulin Resistance
Insulin Therapies → Insulin Resistance
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 5 studies
Explore evidence#7 CGM Time in Range
DPP-4 Inhibitors → CGM Time in Range
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 5 studies
Explore evidence#8 Fasting Glucose
GLP-1 Receptor Agonists → Fasting Glucose
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 69
- Positive
- ConsistencyScore™
- 63
- generally_consistent
Supporting studies: Based on 8 studies
Explore evidence#9 HbA1c
DPP-4 Inhibitors → HbA1c
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 87
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 7 studies
Explore evidence#10 Hypoglycemia
GLP-1 Receptor Agonists → Hypoglycemia
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 12 studies
Explore evidencePractical Questions
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Which outcomes have the strongest evidence for Medications?
evidence strengthStrong Evidence
Body weight and HbA1c have the strongest available evidence signals for Medications.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 87.5 | moderate positive | ConsistencyScore™ Consistent | 11 studies
- 2
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 87.3 | strong positive | ConsistencyScore™ Consistent | 21 studies
Why this answer: This answer is based on 22 supporting studies with consistent results and a positive effect signal.
Applicability
Population details were available for 1 of 22 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....
What outcomes does Medications appear to affect most often?
most studiedEmerging Evidence
Body weight, HbA1c, and Hypoglycemia events are among the most studied areas in relation to Medications.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 87.5 | moderate positive | ConsistencyScore™ Consistent | 33 studies
- 2
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 87.3 | strong positive | ConsistencyScore™ Consistent | 61 studies
- 3
Hypoglycemia events
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak positive | ConsistencyScore™ Consistent | 14 studies
Why this answer: This answer is based on 68 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
Applicability
Population details were available for 2 of 68 supporting studies. Reported populations varied; examples included Participants were adults with type 2 diabetes and high cardiovascular risk recruited from a Shanghai tertiary hospital. Groups were generally balanced at baseline, although hypertension and some background medication... and Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....
Where are results mixed or inconsistent for Medications?
consistency issuesModerate Evidence
Results are mixed or unclear for Coefficient of variation, Time below range, and Time in range in relation to Medications.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The evidence includes both beneficial and harmful or worsening results.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Strong | EvidenceScore™ 82.9 | weak positive | ConsistencyScore™ Mixed | 8 studies
- 2
Nonfatal stroke
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak negative | ConsistencyScore™ Mixed | 4 studies
- 3
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Mixed | 5 studies
Why this answer: This answer is cautious because the available studies report mixed findings.
Applicability
Population details were available for 1 of 39 supporting studies: Participants had longstanding T2D (mean 11.2 years) with inadequate glycemic control (mean HbA1c 7.82%) despite stable GLP-1 RA therapy (dulaglutide) for ≥6 months. Baseline characteristics were balanced between....
Which outcomes need more research for Medications?
research gapsEmerging Evidence
Rate of admission for hypoglycaemia, Rate of breastfeeding at 6 weeks, and Rate of breastfeeding at discharge need more research in relation to Medications.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Rate of admission for hypoglycaemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Rate of breastfeeding at 6 weeks
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
- 3
Rate of breastfeeding at discharge
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
How does Body weight compare with HbA1c for Medications?
compareStrong Evidence
Body weight and HbA1c have available evidence for Medications, but the comparison requires review of the underlying studies.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 87.5 | moderate positive | ConsistencyScore™ Consistent | 11 studies
- 2
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 87.3 | strong positive | ConsistencyScore™ Consistent | 13 studies
Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Outcomes Influenced by Medications
Outcomes most commonly studied in relation to medications interventions.
HbA1c Reduction
EvidenceScore™ 64/100
Evidence related to lowering or improving HbA1c/A1C in diabetes management.
84 Studies
Weight Loss
EvidenceScore™ 63/100
Evidence related to body weight reduction, BMI improvement, waist circumference, and body composition changes.
86 Studies
Cardiovascular Risk
EvidenceScore™ 63/100
Evidence related to cardiovascular risk, cardiovascular events, ASCVD risk, vascular function, functional capacity, and mortality outcomes in diabetes studies.
63 Studies
Glycemic Control
EvidenceScore™ 61/100
Evidence related to blood glucose control, fasting glucose, postprandial glucose, glucose variability, and time in range.
92 Studies
Inflammatory and Vascular Markers
EvidenceScore™ 60/100
Evidence related to inflammatory, oxidative stress, endothelial, and vascular biomarkers measured in diabetes studies.
11 Studies
Treatment Adherence
EvidenceScore™ 59/100
Evidence related to treatment adherence, medication use, physical activity participation, step count, diet intake, fruit and vegetable intake, and self-care behavior adherence.
1 Study
Latest Research
Mulberry twig alkaloids improve glucose control in type 2 diabetes
Published: January 1, 2026
int-mulberry-twig-alkaloids-sz-a
out-blood-glucoseout-body-weight
Semaglutide with Insulin Improves Diabetes Control and Kidney Health
Published: January 1, 2026
int-insulin-therapy
out-24-hour-urinary-protein-24huprout-adverse-events-incidence
Nutritional Therapy and AGIs Improve Postprandial Glucose in Diabetes
Published: January 1, 2026
int-acarboseint-voglibose
out-24-hour-glucoseout-glucose-auc
Mulberry Twig Alkaloids Improve Glycemic Variability in Type 2 Diabetes
Published: January 1, 2026
int-insulin-pump-plus-mulberry-twig-extract-therapy
out-blood-glucoseout-coefficient-of-variation
Novel Semaglutide Injection Shows Non-Inferior Glycemic Control
Published: January 1, 2026
int-semaglutide
out-adverse-events-incidenceout-bmi
Tadalafil may shift neurodegeneration biomarkers in type 2 diabetes
Published: January 1, 2026
int-tadalafil
out-amyloid-beta-40out-amyloid-beta-42
Tirzepatide improves cardiometabolic health in obesity.
Published: January 1, 2026
int-tirzepatide
out-bmiout-body-weight
Dapagliflozin-linagliptin combo improves glycemic control and organ protection
Published: January 1, 2026
int-dapagliflozin
out-alanine-aminotransferase-altout-estimated-glomerular-filtration-rate
HRS-7535 improves glycemic control in adults with type 2 diabetes
Published: January 1, 2026
int-hrs-7535-15-mgint-hrs-7535-30-mg
out-fasting-plasma-glucoseout-hba1c
Early use of effective therapies may improve diabetes outcomes
Published: January 1, 2026
int-metformin
out-bmiout-estimated-glomerular-filtration-rate
Evidence Landscape
Evidence landscape
Each bubble represents an evidence relationship. Position shows effectiveness and EvidenceScoreâ„¢; size reflects study volume.
- Strong evidence
- Moderate evidence
- Limited evidence
Evidence Workspace
Create your evidence workspace
Save evidence topics and organize the research that matters to you.